IFN-beta-dependent inhibition of tumor growth by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).

@article{Roberts2008IFNbetadependentIO,
  title={IFN-beta-dependent inhibition of tumor growth by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).},
  author={Zachary Roberts and L. Y. Ching and Stefanie N. Vogel},
  journal={Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research},
  year={2008},
  volume={28 3},
  pages={133-9}
}
By attacking established tumor vasculature, vascular disrupting agents (VDAs) represent an alternative approach to the treatment of cancer. One such VDA, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), is scheduled for phase III trials for prostate and lung cancer in combination with conventional chemotherapies. In this work, we identify interferon-beta (IFN-beta) as a central mediator in the host's response to DMXAA. In mice bearing Lewis lung adenocarcinomas, a single intraperitoneal dose of… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 47 references

Randomized phase II study of docetaxel with or without DMXAA (AS1404) in hormone-refractory metastatic prostate cancer (HRMPC) [Abstract 219

  • M Rosenthal, R. Pili
  • Am Soc Clin Oncol Prostate Cancer Symposium…
  • 2007
Highly Influential
4 Excerpts

A randomized phase II trial of combretatstatin A4 phosphate (CA4P) in combination with paclitaxel and carboplatin to evaluate safety and efficacy in subjects with advanced imageable malignancies

  • WL Ackerley, M Schabel, +4 authors K. Arbogast
  • J Clin Oncol 25:14060.
  • 2007

Similar Papers

Loading similar papers…